48,862
edits
Difference between revisions of "Prostate cancer"
Jump to navigation
Jump to search
→IHC
(→Extraprostatic extension: tweak) |
(→IHC) |
||
| Line 316: | Line 316: | ||
==IHC== | ==IHC== | ||
===Benign prostate versus neoplastic prostate=== | |||
*AMACR +ve. | *AMACR +ve. | ||
*AR +ve -- in prostate confined cancer. | *AR +ve -- in prostate confined cancer. | ||
| Line 331: | Line 332: | ||
***Why '''CAP'''? | ***Why '''CAP'''? | ||
****A. '''CA'''ncer of the '''P'''rostate. | ****A. '''CA'''ncer of the '''P'''rostate. | ||
====Prostate versus urothelium==== | |||
*PSA. | |||
*CK20. | |||
Note: | |||
*AMACR not useful - positive in ~ 50% of [[UCC]].<ref name=pmid16315020>{{Cite journal | last1 = Langner | first1 = C. | last2 = Rupar | first2 = G. | last3 = Leibl | first3 = S. | last4 = Hutterer | first4 = G. | last5 = Chromecki | first5 = T. | last6 = Hoefler | first6 = G. | last7 = Rehak | first7 = P. | last8 = Zigeuner | first8 = R. | title = Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. | journal = Virchows Arch | volume = 448 | issue = 3 | pages = 325-30 | month = Mar | year = 2006 | doi = 10.1007/s00428-005-0129-6 | PMID = 16315020 }}</ref> | |||
==Molecular changes in prostate cancer== | ==Molecular changes in prostate cancer== | ||